伊布替尼-话题@MedSci

#伊布替尼#

88篇内容 | 4005人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1288726, encodeId=1b551288e2604, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：伊布替尼治疗难治复发滤泡淋巴瘤的有效性, objectType=article, longId=119982, objectId=622411998220, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622411998220, replyNumber=0, likeNumber=73, createdTime=2017-11-16, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622411998220, moduleTitle=Blood：伊布替尼治疗难治复发滤泡淋巴瘤的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622411998220)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288725, encodeId=171e1288e25b2, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：伊布替尼治疗难治复发滤泡淋巴瘤的有效性, objectType=article, longId=119811, objectId=ec3e11981187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec3e11981187, replyNumber=0, likeNumber=60, createdTime=2017-11-14, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec3e11981187, moduleTitle=Blood：伊布替尼治疗难治复发滤泡淋巴瘤的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec3e11981187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288724, encodeId=66cf1288e24ca, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=RAY研究（MCL 3001）：伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究, objectType=article, longId=116559, objectId=340511655922, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=340511655922, replyNumber=0, likeNumber=41, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=340511655922, moduleTitle=RAY研究（MCL 3001）：伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=340511655922)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288723, encodeId=e8c41288e23db, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=PCYC-1104研究：伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果, objectType=article, longId=116558, objectId=7fa2116558d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fa2116558d1, replyNumber=0, likeNumber=62, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fa2116558d1, moduleTitle=PCYC-1104研究：伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fa2116558d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288722, encodeId=7fc01288e22a4, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=RESONATE：伊布替尼治疗伴del17p的rrCLL患者：Ⅱ期开放性多中心研究, objectType=article, longId=116557, objectId=1a0a11655e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0a11655e84, replyNumber=0, likeNumber=54, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0a11655e84, moduleTitle=RESONATE：伊布替尼治疗伴del17p的rrCLL患者：Ⅱ期开放性多中心研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0a11655e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288721, encodeId=455c1288e21ee, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=RESONATE：伊布替尼单药一线治疗CLL患者, objectType=article, longId=116556, objectId=b02f11655638, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b02f11655638, replyNumber=0, likeNumber=79, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b02f11655638, moduleTitle=RESONATE：伊布替尼单药一线治疗CLL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b02f11655638)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288720, encodeId=a6f41288e2088, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=RESONATE：伊布替尼 vs. 奥法木单抗治疗复发/难治CLL, objectType=article, longId=116555, objectId=bb971165556a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb971165556a, replyNumber=0, likeNumber=58, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb971165556a, moduleTitle=RESONATE：伊布替尼 vs. 奥法木单抗治疗复发/难治CLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb971165556a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288719, encodeId=46211288e196c, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼单药治疗初治及rrCLL患者：5年随访结果, objectType=article, longId=116554, objectId=586f11655412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=586f11655412, replyNumber=0, likeNumber=61, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=586f11655412, moduleTitle=伊布替尼单药治疗初治及rrCLL患者：5年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=586f11655412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288718, encodeId=865f1288e1805, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Lancet Oncol：伊布替尼联合BR与BR对比治疗rrCLL/SLL患者：随机对照双盲Ⅲ期研究, objectType=article, longId=116553, objectId=580f11655342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=580f11655342, replyNumber=0, likeNumber=80, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=580f11655342, moduleTitle=Lancet Oncol：伊布替尼联合BR与BR对比治疗rrCLL/SLL患者：随机对照双盲Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=580f11655342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288717, encodeId=5cef1288e1768, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：具有临床活性的BTK抑制剂PCI-32765(伊布替尼)靶向干预慢性淋巴细胞白血病B细胞受体和趋化因子调控的粘附与迁移, objectType=article, longId=116551, objectId=5a2311655152, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a2311655152, replyNumber=0, likeNumber=71, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a2311655152, moduleTitle=Blood：具有临床活性的BTK抑制剂PCI-32765(伊布替尼)靶向干预慢性淋巴细胞白血病B细胞受体和趋化因子调控的粘附与迁移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a2311655152)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288716, encodeId=ac8f1288e1683, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼适应症再次扩大：FDA批准伊布替尼成治疗慢性移植物抗宿主病（cGVHD）的药物, objectType=article, longId=116550, objectId=0a20116550c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a20116550c3, replyNumber=0, likeNumber=65, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a20116550c3, moduleTitle=伊布替尼适应症再次扩大：FDA批准伊布替尼成治疗慢性移植物抗宿主病（cGVHD）的药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a20116550c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288715, encodeId=0e941288e1567, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）, objectType=article, longId=116548, objectId=8f8f1165488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8f1165488a, replyNumber=0, likeNumber=70, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8f1165488a, moduleTitle=靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8f1165488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288714, encodeId=05cb1288e14d0, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, objectType=article, longId=116543, objectId=2f6e116543b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6e116543b5, replyNumber=0, likeNumber=72, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6e116543b5, moduleTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6e116543b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288713, encodeId=3dfb1288e13d6, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, objectType=article, longId=116540, objectId=d02a116540e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02a116540e5, replyNumber=0, likeNumber=66, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02a116540e5, moduleTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02a116540e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288712, encodeId=da6b1288e12c9, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=116538, objectId=1f31116538be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f31116538be, replyNumber=0, likeNumber=53, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f31116538be, moduleTitle=全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f31116538be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288711, encodeId=47d91288e11ac, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究, objectType=article, longId=116537, objectId=dd4711653e32, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd4711653e32, replyNumber=0, likeNumber=57, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd4711653e32, moduleTitle=SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd4711653e32)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288710, encodeId=4f851288e1046, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果（PCYC-1104研究）, objectType=article, longId=113569, objectId=597e1135690b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597e1135690b, replyNumber=0, likeNumber=54, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597e1135690b, moduleTitle=伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果（PCYC-1104研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597e1135690b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288709, encodeId=dfaf1288e09d4, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究(RAY研究, MCL 3001), objectType=article, longId=113568, objectId=9b57113568f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b57113568f5, replyNumber=0, likeNumber=56, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b57113568f5, moduleTitle=伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究(RAY研究, MCL 3001), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b57113568f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288708, encodeId=21921288e085f, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, objectType=article, longId=113567, objectId=c69011356e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69011356e79, replyNumber=0, likeNumber=42, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69011356e79, moduleTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69011356e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288707, encodeId=6cdf1288e0753, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=111399, objectId=185911139962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185911139962, replyNumber=0, likeNumber=45, createdTime=2017-09-01, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185911139962, moduleTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185911139962)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊布替尼

2020-05-29

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：伊布替尼治疗难治复发滤泡淋巴瘤的有效性

2017-11-16

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：伊布替尼治疗难治复发滤泡淋巴瘤的有效性

2017-11-14

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

RAY研究（MCL 3001）：伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

PCYC-1104研究：伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

RESONATE：伊布替尼治疗伴del17p的rrCLL患者：Ⅱ期开放性多中心研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

RESONATE：伊布替尼单药一线治疗CLL患者

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

RESONATE：伊布替尼 vs. 奥法木单抗治疗复发/难治CLL

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼单药治疗初治及rrCLL患者：5年随访结果

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Lancet Oncol：伊布替尼联合BR与BR对比治疗rrCLL/SLL患者：随机对照双盲Ⅲ期研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：具有临床活性的BTK抑制剂PCI-32765(伊布替尼)靶向干预慢性淋巴细胞白血病B细胞受体和趋化因子调控的粘附与迁移

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼适应症再次扩大：FDA批准伊布替尼成治疗慢性移植物抗宿主病（cGVHD）的药物

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果（PCYC-1104研究）

2017-09-23

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究(RAY研究, MCL 3001)

2017-09-23

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）

2017-09-23

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-09-01

科室
- - 订阅+
  - 更多科室
工具
服务